MedTrace Logo

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer

NCT06262633 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2025-05-06

No results posted yet for this study

Summary

This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

Conditions

Interventions

DEVICE

Targeted Microwave Ablation (TMA) for localized prostate cancer using organ based tracking (OBT) navigation

Targeted microwave ablation (TMA) is a novel treatment developed for focal treatment of prostate cancer, and it is applied with precise navigation guidance under the organ-based tracking (OBT) mechanism.

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Peter Ka-Fung CHIU, PhD,MBChB · Chinese University of Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2026-04-30
Completion
2026-06-30

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06262633 on ClinicalTrials.gov